Natural occurrence of drug resistance mutations to the HIV-1 capsid inhibitor lenacapavir.

ABSTRACT:

Aims

Lenacapavir (LEN) is a first-in-class HIV-1 capsid inhibitor. We investigated the natural occurrence of LEN drug resistance mutations (DRM) in HIV-1 sequences from LEN treatment-naïve individuals.

Methods

We analysed all available HIV-1 capsid sequences (n = 21 646) from individuals never exposed to LEN from the Los Alamos National Laboratory database.

Results

LEN DRMs were identified at all LEN DRM-associated positions, including the highly resistant M66I variant, which was found in 9 sequences across multiple subtypes. In total, 56 sequences (0.26%) contained LEN DRMs. The most prevalent mutation was Q67H (n = 22), and this mutation was more common in CRF01_AE (17/3053, 0.56%).

Conclusions

All known LEN DRMs can be found in viral populations without drug

SUBMITTER: Weibull Warnberg A 

PROVIDER: S-EPMC12579888 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature